apatinib + letrozole + fluzoparib

apatinib + letrozole + fluzoparib is a combination therapy being investigated for the treatment of estrogen receptor (ER)-positive, platinum-sensitive recurrent ovarian cancer. The regimen consists of fluzoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor; apatinib, a selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2 (VEGFR-2); and letrozole, a third-generation aromatase inhibitor. This triple-combination approach, studied in clinical trials led by Peking Union Medical College Hospital, aims to provide a maintenance therapy option for patients who have progressed after initial PARP inhibitor treatment by simultaneously inhibiting DNA repair, angiogenesis, and estrogen-driven tumor growth. The combination is designed to overcome resistance mechanisms that often emerge during single-agent PARP inhibitor maintenance.

Other names

Apatinib plus letrozole plus fluzoparibApatinib, letrozole, and fluzoparib combinationfuzuloparib + apatinib + letrozole